Table 2 Summary of included RCTs
PARP Inhibitors | Number of Phase II Studies | Number of Phase III Studies | Sample Size (PARP group/control group) | Interventions | Median treatment duration (PARP group) | Cancer | |
|---|---|---|---|---|---|---|---|
Treatment regime (PARP group versus control group) | Number of studies | ||||||
Niraparib | 0 | 4 | 1153/571 | A | 4 | 44Â days, 369Â days | Ovarian cancer, Lung Cancer |
Olaparib | 8 | 6 | 2418/1726 | A | 5 | 8 weeks ~ 24.6 months | Ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, breast cancer, and gastric cancer |
B | 3 | ||||||
C | 6 | ||||||
Veliparib | 7 | 3 | 1953/1275 | C | 10 | 8 weeks ~ 36 weeks | Ovarian cancer, breast cancer, prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, pancreas adenocarcinoma |
Rucaparib | 0 | 3 | 1029/412 | A | 2 | 7.3 months ~ 14.7 months | Ovarian cancer, peritoneal cancer |
B | 1 | ||||||
Iniparib | 1 | 0 | 78/39 | C | 1 | 15Â weeks | Lung cancer |
Totle | 16 | 16 | 6631/4023 | A,B,C | 32 | 44 days ~ 14.7 months | Ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, breast cancer, peritoneal cancer, colorectal cancer, gastric cancer, pancreas adenocarcinoma |